SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: jake burns who wrote (1004)8/1/1998 2:21:00 PM
From: Peter Singleton  Respond to of 1510
 
jake,

I'll take a crack at that. assuming the overall market is flat or positive, my guess is that IMNR would start a run upward upon both the release of approvable clinical results and the panel review (if there is one). Don't know if the NDA itself would be an inflection point on the stock. Approval after a favorable panel review (once again, if there is one) would probably be substantially discounted into the stock.

imo, of course.

Peter



To: jake burns who wrote (1004)8/11/1998 3:05:00 PM
From: Texas77  Read Replies (2) | Respond to of 1510
 
jake,

Last time you said buy - it was dead on. Is it time again. Stock sure acting like it wants to explode from these levels!!!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News